X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LAM-001 (sirolimus) is a proprietary, investigational, inhaled formulation of sirolimus, which is investigated in Patients With pulmonary arterial hypertension.
Lead Product(s): Sirolimus
Therapeutic Area: Cardiology/Vascular Diseases Product Name: LAM-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2023
Details:
LAM-001 (sirolimus) is a proprietary, investigational, inhaled formulation of sirolimus, which is investigated in Patients With Bronchiolitis Obliterans Syndrome (BOS) Post-Lung Transplant.
Lead Product(s): Sirolimus
Therapeutic Area: Immunology Product Name: LAM-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2023
Details:
AIT-101 (apilimod dimesylate) is a potent and highly selective inhibitor of the lipid kinase PIKfyve, which activates the transcription factor TFEB which drives the increased clearance of toxic protein aggregates. It is being investegated for treating C9ORF72 ALS.
Lead Product(s): Apilimod mesylate
Therapeutic Area: Neurology Product Name: AIT-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2023
Details:
EC-8042 (redesignated AIT-102), is a targeted cancer therapy that inhibits the activity of SWI/SNF in certain tumors where SWI/SNF is mutated (such as Rhabdoid tumors) and in other tumors where SWI/SNF associates with oncogenic transcription factors.
Lead Product(s): AIT-102
Therapeutic Area: Oncology Product Name: AIT-102
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: EntreChem
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 25, 2022
Details:
The randomized, double-blind, placebo-controlled study will enroll up to 142 outpatients to evaluate the safety, tolerability, and efficacy of LAM-002A in reducing viral load in subjects with a confirmed COVID-19.
Lead Product(s): Apilimod mesylate
Therapeutic Area: Infections and Infectious Diseases Product Name: LAM-002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2020
Details:
The company has made significant recent progress on its four clinical assets and proprietary Guardian Angel™ algorithm.
Lead Product(s): Sirolimus
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
